Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Bristol Myers Squibb : U.S. Patents Awarded to Inventors in Connecticut (Nov. 10)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:38pm CEST

ALEXANDRIA, Va., Nov. 10 -- The following federal patents were awarded to inventors in Connecticut.

***

Temptime Assigned Patent for Computing Systems

ALEXANDRIA, Va., Nov. 10 -- Temptime, Morris Plains, New Jersey, has been assigned a patent (9,811,632) developed by six co-inventors for "computing systems and methods for electronically indicating the acceptability of a product." The co-inventors are Frederick Robert Grabiner, Livingston, New Jersey, Carl Michael Lentz, Cedar Knolls, New Jersey, Emily Moore, Haddam, Connecticut, Thaddeus Prusik, Stroudsburg, Pennsylvania, Nicholas Puro, Briarcliff Manor, New York, and Bruce-Erik Osborn, West Vancouver, Canada. The abstract states: "In part, the invention relates to computing systems and methods for electronically indicating the acceptability of a product. An image capture and communication device may analyze a product label that includes one or more monitors, authentication elements, and identification elements. The image capture and communication device may determine the type and features of the monitors, authentication elements, and identification elements. The image capture and communication device may transmit data based on the type and features to a host server, which may transmit data associated with the host product to the image capture and communication device in, inter alia, the form of an acceptability report."

The patent application was filed on Dec. 28, 2015 (14/981,457). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,811,632.PN.&OS=PN/9,811,632&RS=PN/9,811,632

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Immunomodulators

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,625) developed by two co-inventors for immunomodulators. The co-inventors are Kenneth M. Boy, Durham, Connecticut, and Paul Michael Scola, Glastonbury, Connecticut. The abstract states: "The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases."

The patent application was filed on March 14, 2016 (15/068,993). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,625.PN.&OS=PN/9,809,625&RS=PN/9,809,625

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,573) developed by six co-inventors for "substituted pyridine derivatives useful as GSK-3 inhibitors." The co-inventors are Guanglin Luo, Madison, Connecticut, Ling Chen, Middletown, Connecticut, Gene M. Dubowchik, Middlefield, Connecticut, Swanee E. Jacutin-Porte, Madison, Connecticut, Prasanna Sivaprakasam, Middletown, Connecticut, and John E. Macor, Washington Crossing, Pennsylvania. The abstract states: "The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system."

The patent application was filed on Nov. 3, 2014 (15/033,770). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,573.PN.&OS=PN/9,809,573&RS=PN/9,809,573

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

P.F. Laboratories, Purdue Pharma, Purdue Pharmaceuticals Assigned Patent for Pharmaceutical Formulation Containing Opioid Agonist

ALEXANDRIA, Va., Nov. 10 -- P.F. Laboratories, Totowa, New Jersey, Purdue Pharma, Stamford, Connecticut, and Purdue Pharmaceuticals, Wilson, North Carolina, have been assigned a patent (9,808,453) developed by three co-inventors for "pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent." The co-inventors are Benjamin Oshlack, Boca Raton, Florida, Curtis Wright, Rockport, Massachusetts, and Christopher Breder, Greenwich, Connecticut. The abstract states: "Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid."

The patent application was filed on Dec. 19, 2016 (15/384,229). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,453.PN.&OS=PN/9,808,453&RS=PN/9,808,453

Written by Amal Ahmed; edited by Sudarshan Harpal.

TARGETED NEWS SERVICE: Myron Struck, editor; 703/304-1897; [email protected]; http://www.targetednews.com

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
04:39pBRISTOL MYERS SQUIBB : Myers, AbbVie eye new use for myeloma drug Empliciti afte..
AQ
01:41pBRISTOL-MYERS SQUIBB COMPANY : - China National Drug Administration Approves Cou..
AQ
01:00pBRISTOL MYERS SQUIBB : Dallas Cowboys Quarterback Dak Prescott, Modern Family St..
BU
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19THE GLOBAL ORGAN PRESERVATION MARKET : Some of the key players in Global Organ P..
AQ
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/17BRISTOL MYERS SQUIBB : Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dex..
BU
06/15BRISTOL MYERS SQUIBB : China National Drug Administration Approves Country&rsquo..
BU
06/15BRISTOL MYERS SQUIBB : to Present New Research Findings on the Treatment of Pati..
AQ
06/14BRISTOL MYERS SQUIBB : Trademark Application for "OBREFCO" Filed by Bristol-Myer..
AQ
More news
News from SeekingAlpha
08:00aYOUR DAILY PHARMA SCOOP : TG Therapeutics Phase 2 Results, Geron Positive, Agio .. 
06/19Idera Stock Has Declined Since Failure Of Phase 2 Trial In Rare Disease, But .. 
06/18Bristol-Myers Squibb's Empliciti reduced risk of cancer progression in mid-st.. 
06/17WEEK IN REVIEW : Mevion Medical Of Boston Closes $150 Million Financing From Chi.. 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
Financials ($)
Sales 2018 21 740 M
EBIT 2018 5 499 M
Net income 2018 4 486 M
Finance 2018 428 M
Yield 2018 3,04%
P/E ratio 2018 18,95
P/E ratio 2019 16,13
EV / Sales 2018 4,01x
EV / Sales 2019 3,70x
Capitalization 87 693 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 57,3 $
Spread / Average Target 6,9%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-12.45%87 693
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
MERCK AND COMPANY8.46%164 082